Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Defining Bronchioloalveolar Carcinoma (BAC): One End of a Spectrum
October 11, 2006, 11:29 AM
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

The clinical syndrome of BAC is characterized by spread primarily through the lungs, a higher proportion of never-smokers or light former smokers, a greater proportion of women, and often progresses more slowly than most other lung cancers. This clinical and radiographic (scans) scenario isn't necessarily seen only with “pure BAC” under the microscrope from a biopsy, but rather can be a spectrum from pure BAC to part non-invasive BAC pattern and part invasive adenocarcinoma, and on the other end of the continuum is invasive adenocarcinoma, as shown in the illustration of how these appear under a microscope.

Pure BAC Adenocarcinoma w/BAC Features Invasive Adenocarcinoma
Pure BAC Adeno w/BAC Features Invasive Adeno

It doesn't have to be "pure BAC" to behave like a BAC clinical picture. The variability in how BAC behaves is still poorly understood. Overall, invasive adenocarcinoma (without BAC) has a worse prognosis than adeno/BAC mix, but there's tons we don't know yet. Importantly, many of the amazing responders with what is called BAC actually have adenocarcinoma with BAC characteristics under the microscope. And the response rate on BAC trials of drugs like Iressa (gefitinib) and Tarceva (erlotinib) actually suggest that patients with adenocarcinoma with BAC characteristics may do better than pure BAC. One of the other complications is that there are two different types of pure BAC, mucinous and nonmucinous. In the BAC trial with Iressa, which I led and published recently, patients with mucinous pure BAC did very poorly, while those with the non-mucinous type did considerably better. In any event, most current trials for "patients with BAC" allow patients with pure BAC or adeno with BAC to participate, and then the trial tries to collect tissue from the tumors to figure out patterns of which patients are getting a benefit and which are not. Right now, we really don't know nearly enough about the different subtypes of BAC and how they will do with various treatments. But we're getting better all the time.

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

The forum was a big success. If you weren't able to attend the live session we'll have an on-demand version available soon.
If you have questions that weren't addressed please ask...

Hi Everyone, I'm glad you have found this thread and sorry that you need to be here. 


 


We've got the forum up for on-demand streaming. This full version will be...

Hi JGromo, Welcome to Grace. I'm so sorry your dad and by extension, you are going through this. If it helps, I know how you feel. My husband is going through...

I agree that not all docs are good communicators! Remember they are people just like us, filling a very important role. I echo Janine's comment to ask questions here -- our...

While no one can give advice or recommend treatments on a forum our faculty can be invaluable when talking about current thought and practices.


 


This is the response via email...

Recent Comments

JOIN THE CONVERSATION
Hi szhang, I'm glad your dad…
By JanineT Forum … on Wed, 03/15/2023 - 09:52
Hi Everyone,
I wanted to…
By szhang123 on Tue, 03/14/2023 - 20:06
Full version is now on-demand
By JanineT Forum … on Mon, 03/06/2023 - 12:27
We'll have an on demand version available soon
By JanineT Forum … on Sun, 02/26/2023 - 06:52